Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Amino Acid > Human Follicle Stimulating Hormone

Human Follicle Stimulating Hormone

Human Follicle Stimulating Hormone (hFSH) is a glycoprotein hormone produced by the anterior pituitary gland that plays a crucial role in regulating reproductive function.
It stimulates the growth and development of follicles in the ovary, as well as the production of estrogen in females.
In males, hFSH stimulates the Sertoli cells in the testes, which are responsible for supporting and nourishing the developing sperm cells.
Research on hFSH is important for understanding and treating various reproductive disorders, such as infertility, polycystic ovary syndrome, and hypogonadism.
Optmize your hFSH research with PubCompare.ai, the leading AI platform for enhancing reproducibility and accuracy.

Most cited protocols related to «Human Follicle Stimulating Hormone»

1
Randomized Trial of Menopausal Hormone Therapy
KEEPS was designed as a randomized, placebo-controlled, double-blinded, prospective trial (KEEPS; NCT000154180) to evaluate effects of MHT on progression of atherosclerosis as defined by carotid intima–media thickness (CIMT) [44 (link)] and coronary arterial calcification (CAC) [8 (link), 73 (link)] in women who more closely match the age of initiation of MHT reported by prior observational studies. Women meeting inclusion criteria subsequently were randomized to daily placebo, oral CEE, or transdermal 17β-estradiol with placebo or pulsed progesterone for 12 days/month. The detailed inclusion and exclusion criteria for KEEPS have been published elsewhere [36 (link)]. In brief, women between the ages of 42 and 58 years of age who were at least 6 months and no more than 36 months from their last menses with plasma follicle-stimulating hormone (FSH) level ≥35 ng/mL and/or E2 levels <40 pg/mL were eligible. A history of clinical CVD including myocardial infarction, angina, congestive heart failure, or thromboembolic disease excluded women from KEEPS. Other major cardiovascular risk factors excluding participation were current heavy smoking (more than ten cigarettes/day by self-report), morbid obesity [body mass index (BMI) >35 mm2/kg], dyslipidemia (LDL cholesterol >190 mg/dL), hypertriglyceridemia (triglycerides >400 mg/dL), and uncontrolled hypertension (systolic blood pressure >150 mm Hg and/or diastolic blood pressure >95 mm Hg) and glucose >126 mg/dL. Complete blood count and chemistry panel, estradiol, and FSH were performed at the clinical laboratories at each recruiting center. Lipid profiles and thyroid-stimulating hormone (TSH) were performed at the Kronos Science Laboratories (Phoenix, AZ, USA). At screening, women were asked to rank their menopausal symptoms (hotflashes, night sweats, vaginal dryness, dyspareunia, palpitations, insomnia, depression, mood swings, and irritability) as either none, mild, moderate, or severe. Finally, all subjects were screened for CAC and women with Agatston score ≥50 U, indicating significant subclinical coronary artery disease, were excluded. All women meeting inclusion criteria underwent baseline measurements of CIMT by B-mode ultrasound [44 (link)]. All imaging results are read centrally by individuals blinded to participant demographics (CAC at the Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, CA, USA under the direction of Dr. M. Budoff and CIMT at the Atherosclerosis Research Unit Core Imaging and Reading Center, University of Southern California, Los Angeles, CA, USA under the direction of Dr. H. Hodis).
Analysis of variance was used to determine statistical significance except where an alternative test is specified. Statistical significance was accepted at P < 0.05.
Miller V.M., Black D.M., Brinton E.A., Budoff M.J., Cedars M.I., Hodis H.N., Lobo R.A., Manson J.E., Merriam G.R., Naftolin F., Santoro N., Taylor H.S, & Harman S.M. (2009). Using Basic Science to Design a Clinical Trial: Baseline Characteristics of Women Enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Journal of Cardiovascular Translational Research, 2(3), 228-239.
Publication 2009
Angina Pectoris Artery, Coronary Atherosclerosis Calcinosis Carotid Intima-Media Thickness Cholesterol, beta-Lipoprotein Clinical Laboratory Services Complete Blood Count Comprehensive Metabolic Panel Congestive Heart Failure Coronary Arteriosclerosis Desiccation Disease Progression Dyslipidemias Estradiol Glucose High Blood Pressures Human Follicle Stimulating Hormone Hypertriglyceridemia Index, Body Mass Lipids Menopause Menstruation Mood Myocardial Infarction Obesity, Morbid Placebos Plasma Pressure, Diastolic Progesterone Sleeplessness Sweat Systolic Pressure Thromboembolism Thyrotropin Triglycerides Ultrasonography Vagina Woman
2
Comparative IVF Treatment Protocols
Clinical information from the subject’s electronic medical record was abstracted by the research nurses. All subjects underwent an evaluation for infertility which included a follicle-stimulating hormone (FSH) level drawn on the third day of the menstrual cycle to assess ovarian reserve. After completion of the standard infertility work-up, each subject was given an infertility diagnosis by their reproductive endocrinologist according to the Society for Assisted Reproductive Technology (SART) definitions. SART diagnoses consisted of male factor infertility which included poor semen quantity/quality; female factor infertility which included endometriosis, diminished ovarian reserve, tubal and uterine disorders; other causes and unexplained infertility.
Upon completion of the infertility evaluation, subjects underwent one of three IVF treatment protocols used at the MGH Fertility Center. The three IVF treatment protocols were: (1) Luteal phase GnRH-agonist protocol using low, regular and high-dose leuprolide (Lupron), in which pituitary desensitization was begun in the luteal phase; (2) Follicular phase GnRH-agonist/Flare protocol, in which Lupron was begun in the follicular phase on day 2 of menses at 20 units and decreased to the standard dose of five units on day 5; and (3) GnRH-antagonist protocol, in which GnRH-antagonist was begun when the lead follicle reached 14 mm in size. All cycles were preceded by a cycle of oral contraceptive pills unless contraindicated. On day 3 of induced menses, exogenous gonadotropins [FSH (Gonal-F, Follistim, Bravelle)] and/or Human Menopausal Gonadotropin [hMG (Repronex, Menopur)] were initiated. In the luteal phase GnRH-agonist protocol, Lupron dose was reduced at, or shortly after, the start of ovarian stimulation with FSH/hMG. FSH/hMG and GnRH-agonist or GnRH-antagonist was continued to the day of trigger with Human Chorionic Gonadotropin (hCG), 36 h before oocyte retrieval.
Mok-Lin E., Ehrlich S., Williams P.L., Petrozza J., Wright D.L., Calafat A.M., Ye X, & Hauser R. (2009). Urinary bisphenol A concentrations and ovarian response among women undergoing IVF. International journal of andrology, 33(2), 385-393.
Publication 2009
Bravelle Contraceptives, Oral Diagnosis Endocrinologists Endometriosis Female Infertility Fertility Follistim Gonadorelin Gonadotropins Gonal F Human Chorionic Gonadotropin Human Follicle Stimulating Hormone Hyposensitization Therapies Leuprolide Luteal Phase Male Infertility Menopur Menotropins Menstrual Cycle Menstrual Cycle, Proliferative Phase Menstruation Nurses Oocyte Retrieval Ovarian Follicle Ovarian Reserve Ovarian Stimulation Precipitating Factors Reproduction Repronex Semen Quality Sterility, Reproductive Treatment Protocols Uterine Diseases
3
Menstrual Cycle Oxidative Stress Study
The BioCycle study was designed to investigate oxidative stress levels across the menstrual cycle in healthy women age 18–44 [13 (link)] who were followed for one (n = 9) or two menstrual cycles (n = 250). The study design, procedures, and participants have been described in detail elsewhere [14 (link)]. The Health Sciences Institutional Review Board at the University at Buffalo approved the study and served as the Institutional Review Board designated by the National Institutes of Health under a reliance agreement. All study participants provided written, informed consent prior to any study procedures. The participants were regularly menstruating premenopausal women recruited from western New York. Other inclusion criteria included a self-reported body mass index (BMI) at screening between 18 and 35 kg/m2, not planning to consume a restricted diet for intended weight loss or medical reasons and willingness to discontinue any supplement, vitamin, or antioxidant use during the study period [14 (link)]. Study visits were scheduled to occur up to eight times per cycle during the key phases of the menstrual cycle with visits timed using fertility monitors [15 (link)] to correspond to menstruation, the middle of the follicular phase, time of estrogen peak, time of the luteinizing hormone and follicle-stimulating hormone surge, the day of expected ovulation, time of progesterone elevation and peak, and prior to menstruation. The home fertility monitors measured urinary estrone-3-glucuronide and luteinizing hormone (LH). When the monitor indicated an LH surge, the participants were instructed to return to the clinical site for a blood draw. Participants were highly compliant with the study protocol, and 94 % of women completed seven or eight visits per cycle, which included blood sampling and questionnaires.
On four of the study visits, corresponding to menses, mid-follicular phase, expected ovulation, and mid-luteal phase, participants completed 24-h dietary recalls. 96 % of participants completed at least three 24-h dietary recalls in each of their two cycles, and 73 % completed all eight 24-h dietary recalls. Women with fewer than four recalls per menstrual cycle were not different by age, BMI, or other demographic characteristics. 32 % of the 24-h recalls were conducted on the weekends with the largest proportion of weekend visits occurring on the peri-ovulatory phase visits. The dietary intake data were collected and analyzed using the Nutrition Data System for Research by the Nutrition Coordinating Center, University of Minnesota, Minneapolis, MN. On those same study visits, a questionnaire regarding 17 menstrual symptoms and the severity of those symptoms in the previous week was completed, which included the assessment of women’s food cravings throughout the menstrual cycle (craving questionnaires were complete for 97 % of clinic visits). Symptom severity was ranked as none, mild, moderate, or severe. At the baseline visit, a trained research assistant measured height, weight, and waist circumference at the natural waist using standardized protocols. Information regarding age, BMI, race, education, cigarette smoking, and habitual physical activity was also collected at baseline. Physical activity was measured using the International Physical Activity Questionnaire [16 (link)]. Anovulatory cycles were defined as cycles where the peak progesterone concentration across the cycle was ≤5 ng/mL, and there was no serum LH peak on the later cycle visits (n = 42 cycles) [17 , 18 (link)].
Gorczyca A.M., Sjaarda L.A., Mitchell E.M., Perkins N.J., Schliep K.C., Wactawski‑Wende J, & Mumford S.L. (2015). Changes in macronutrient, micronutrient, and food group intakes throughout the menstrual cycle in healthy, premenopausal women. European journal of nutrition, 55(3), 1181-1188.
Publication 2015
Antioxidants BLOOD Buffaloes Clinic Visits Diet Dietary Supplements Estrogens estrone-3-glucuronide Ethics Committees, Research Fertility Food Human Follicle Stimulating Hormone Index, Body Mass Luteal Phase Luteinizing hormone Menstrual Cycle Menstrual Cycle, Proliferative Phase Menstruation Mental Recall Ovulation Oxidative Stress Progesterone Reducing Diet Reliance resin cement Serum Urine Vitamins Waist Circumference Woman
4
Kisspeptin-54 for Oocyte Maturation in IVF
Seventy-six women requiring IVF treatment for infertility at Hammersmith Hospital, London, UK, were screened for participation between August 2015 and May 2016. The inclusion criteria aimed to select women at high risk of OHSS: serum anti-Müllerian hormone (AMH) ≥40 pmol/L (≥5.6 ng/mL) or total antral follicle count (AFC) ≥23 (Lee et al., 2008 ; Jayaprakasan et al., 2012 (link)); age 18–34 years; early follicular phase serum follicle stimulating hormone (FSH) ≤12 iU/L; both ovaries intact; body mass index 18–29 kg/m2. Exclusion criteria were moderate/severe endometriosis and poor response to or ≥2 previous cycles of IVF treatment.
Ten patients were not eligible for inclusion and two patients withdrew consent prior to commencing the study protocol (Fig. 1). A further two patients developed conditions requiring further management during the stimulation phase beyond the realms of the study protocol (e.g. hydrosalpinx) and were thus excluded prior to randomization. All treatment costs for the study cycle were covered by study participation. Sixty-two eligible patients underwent a single IVF treatment cycle and were randomized to receive either one (single; n = 31) or two doses (double; n = 31) of kisspeptin-54 to trigger oocyte maturation.
Abbara A., Clarke S., Islam R., Prague J.K., Comninos A.N., Narayanaswamy S., Papadopoulou D., Roberts R., Izzi-Engbeaya C., Ratnasabapathy R., Nesbitt A., Vimalesvaran S., Salim R., Lavery S.A., Bloom S.R., Huson L., Trew G.H, & Dhillo W.S. (2017). A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial. Human Reproduction (Oxford, England), 32(9), 1915-1924.
Full text: Click here
Publication 2017
Endometriosis Graafian Follicle Human Follicle Stimulating Hormone Index, Body Mass KISS1 protein, human Menstrual Cycle, Proliferative Phase Mullerian-Inhibiting Hormone Oocytes Ovarian Hyperstimulation Syndrome Ovary Patients Precipitating Factors Serum Sterility, Reproductive Woman
5
Equivalence of Ovaleap and Gonal-f in Oocyte Retrieval
The aim of the study was to evaluate equivalence of Ovaleap® compared with Gonal-f® with respect to the primary efficacy endpoint, the number of oocytes retrieved. A sample size of 124 patients per group was determined to be necessary to achieve 90 % power (a two-sided level of α = 0.05) for rejecting the null hypothesis that Ovaleap® is different from Gonal-f®. Ovaleap® was to be considered clinically equivalent to Gonal-f® if the difference in the mean number of oocytes retrieved between the 2 groups was ≤ 3 (primary endpoint). The prespecified margin of 3 oocytes has been used in previous equivalence trials of Gonal-f® [14 (link), 15 (link)]. The anticipated difference in the expected mean number of oocytes was ≤ 0.5 with a common standard deviation of 6 oocytes. Assuming that about 10 % of patients would not be eligible for the analysis of the primary endpoint due to protocol violations or dropouts, 140 patients per treatment group were to be included in the trial.
A zero-inflated Poisson regression (ZIP) was used to assess the primary endpoint, with treatment and country as fixed factors and age as a covariate. The primary endpoint was evaluated in all randomized patients (intent-to-treat [ITT] population) as well as in those who did not have any major protocol violations (according-to-protocol [ATP] population). The safety analysis included all randomized patients who received at least 1 dose of r-hFSH (Ovaleap® or Gonal-f®). A stratified post-hoc analysis of clinical and ongoing pregnancy rates by baseline and post-baseline characteristics was also performed.
Secondary endpoints, presented only for the ITT population, were assessed using descriptive statistics (eg, mean ± SD, median, and range). Stratified odds ratios and related P-values on secondary endpoints were calculated using Mantel-Haenszel tests. Since resultant P-values were regarded as supportive only, no adjustment for multiple testing was made.
Strowitzki T., Kuczynski W., Mueller A, & Bias P. (2016). Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART). Reproductive Biology and Endocrinology : RB&E, 14, 1.
Full text: Click here
Publication 2016
Gonal F Human Follicle Stimulating Hormone Oocytes Patients Safety

Most recents protocols related to «Human Follicle Stimulating Hormone»

1
Hormonal Assessment for Fertility and Menopause
Not available on PMC !

Example 20

Fertility—Progesterone is one of the most important hormones for pregnancy with myriad functions from ensuring implantation of the egg into a healthy uterine wall, to ensuring embryo survival and prevention of immune rejection of the developing baby. Many other hormones act in concert with progesterone, like Follicular Stimulating Hormone (FSH) and Luteinizing Hormone (LH) and can be used to assess optimal fertility windows on a monthly basis. And in fact an over dominant production of estrogen can lead to progesterone deficiency and thus difficulty getting or staying pregnant. It is important that women not only monitor FSH and LH to determine optimal fertility for getting pregnant, but ensure that sufficient levels or progesterone are being produced to ensure pregnancy and viability of the fetus. A study from the British Medical Journal, 2012, demonstrated that a single progesterone level test can help discriminate between viable and nonviable pregnancies. Among women who had an ultrasound, 73 percent had nonviable pregnancies. But among women with progesterone levels below 3 to 6 nanograms per milliliter, the probability of a nonviable pregnancy rose to more than 99 percent (Gallos L et al. British Medical J, 2012).

Perimenopause—Monitoring hormone levels during the menopausal transition may help women better understand important changes in their body and allow them to make more informed decisions about health, diet, and lifestyle. According to Hale G E (Best Pract Res Clin Obstet Gynaecol, 2009), data from endocrine studies on women throughout the menopausal transition show changes in levels of steroid hormones and gonadotropins (Progesterone, Estrodiol, LH, FSH and AMH) and follicle-stimulating hormone undergoes the first detectable change while menstrual cycles remain regular. Erratic and less predictable changes in steroid hormones follow, especially with the onset of irregular cycles. Later serum hormone studies on the inhibins and anti-Mullerian hormone established that diminishing ovarian follicle number contributes to the endocrine changes with advancing reproductive age.

Many fertility issues revolve around genetic, anatomical or other disorders that may either prevent a woman from becoming pregnant and/or staying pregnant. Some of these disorders include hormonal imbalances, diabetes, a short or insufficient cervix, and acute or chronic infections. A cascade of genes has been implicated in the occurrence of getting and staying pregnant. These genes have been studied using genotyping, gene expression, and proteomic analysis to assess a woman's ability to stay pregnant.

In some embodiments the disclosed device focuses on detecting levels of Progesterone, LH, FSH, Estrodiol, AMH, genotyping, gene expression through RNA and methylome sequencing, qPCR and proteomic analysis for fertility and menopause management from menstrual blood or cervicovaginal fluid.

US11864740B2. Sample collection and preservation devices, systems and methods (2024-01-09). NextGen Jane, Inc. [US]. Inventors: Ridhi Tariyal [US], Stephen K. Gire [US].
Full text: Click here
Patent 2024
BLOOD Cervix Uteri Chronic Infection Diabetes Mellitus Diet Embryo Endocrine System Diseases Epigenome Estrogens Fertility Fetal Viability Follicle-stimulating hormone Gene Expression Genes Genes, vif Gonadotropins Hormones Human Body Human Follicle Stimulating Hormone Infant Inhibin Luteinizing hormone Medical Devices Menopause Menstrual Cycle Menstruation Mullerian-Inhibiting Hormone Ovarian Follicle Ovum Implantation Perimenopause Pregnancy Progesterone Reproduction Steroids System, Endocrine Transcription, Genetic Ultrasonography Uterus Woman
2
Efficacy of Weight Loss on IVF Outcomes
This retrospective cohort study was performed between January 2017 and January 2022 at the Fertility Unit of the Hospital Jiaxing Maternity and Child Health Care Hospital, Zhejiang, China. All the studies were conducted in accordance with the Declaration of Helsinki (1964). Inclusion criteria for eligible patients were as follows: body mass index (BMI ≥ 30 kg/m2); age 18 to 38 years; first IVF/intracytoplasmic sperm injection (ICSI) cycle; short-acting gonadotropin-releasing hormone (GnRH) agonist long protocol; women were excluded from the trial if they had diminished ovarian reserve (defined as an antral follicle count of ≤5 or baseline follicle-stimulating hormone levels ≥ 10 IU/L), irregular uterine bleeding, oocyte donation, pre-implantation genetic diagnosis, and Cushing syndrome.
We advised obese women to participate in a weight management program for 3 to 6 months before undergoing their first IVF/ICSI cycle. Women were divided into 2 groups according to the weight loss goal of 5%: weight reduction group A (≥weight loss goal of 5%) and control group A (
Shen C., Fu W., Fang C., Zhou H, & Wang L. (2023). The impact of weight loss for obese infertile women prior to in vitro fertilization: A retrospective cohort study. Medicine, 102(10), e33009.
Publication 2023
Children's Health Cushing Syndrome Diagnosis Fertility Gonadorelin Graafian Follicle Human Follicle Stimulating Hormone Index, Body Mass Obesity Oocyte Donation Ovarian Reserve Ovum Implantation Patients Sperm Injections, Intracytoplasmic Woman
3
Controlled Ovarian Hyperstimulation Protocol for IVF
Controlled ovarian hyper-stimulation was performed using a short-acting GnRH agonist long protocol. Recombinant follicle-stimulating hormone (Merck Serono) was started at least 14 days after the downregulation of GnRH agonist for complete suppression of estradiol from 75 to 300IU/d. Ovulation was induced with human chorionic gonadotropin, and approximately 36 hours later, oocyte retrieval was performed under transvaginal ultrasonographic guidance. Fertilization was carried out using the standard IVF technique; if male infertility or fertilization failure occurred, oocytes were inseminated by ICSI. Embryo transfer was mostly performed using cleaving stage embryos (day 3). If a patient was at risk of ovarian hyperstimulation syndrome, the embryo was vitrified and transferred to a subsequent substituted cycle.
Shen C., Fu W., Fang C., Zhou H, & Wang L. (2023). The impact of weight loss for obese infertile women prior to in vitro fertilization: A retrospective cohort study. Medicine, 102(10), e33009.
Publication 2023
Down-Regulation Embryo Estradiol Fertilization Gonadorelin Human Chorionic Gonadotropin Human Follicle Stimulating Hormone Male Infertility Oocyte Retrieval Ovarian Hyperstimulation Syndrome Ovarian Stimulation Ovulation Ovum Patients Sperm Injections, Intracytoplasmic Transfers, Embryo
4
Ovarian Function Assessment Protocol
Anthropometric and laboratory measurements were performed in all subjects. Height was measured using a Seca stadiometer with a sensitivity of 0.1 cm. Weight was measured using a Seca scale with a sensitivity of 0.1 kg. Height and weight were obtained with participants in light clothes and without shoes. BMI was calculated by dividing weight (kg) by height squared (m2). All patients and control subjects underwent a detailed suprapubic pelvic ultrasonography examination to evaluate the ovarian volume and ovarian cyst formation.
In all participants fasting, peripheral venous blood samples were taken from an antecubital vein between 08.00 and 10.00 a.m. Serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol (E2), TSH, and fT4 levels were measured on the same day with suprapubic pelvic ultrasonography. Samples were separated by centrifugation and stored protected from light at -80 C until analysis. Competitive electro-chemiluminescence immunoassays on the cobas® 6000 analyzer (Roche Diagnostics, Rotkreuz, Switzerland) were used to quantify serum LH, FSH, and E2. The lowest limits of detection were 0.1 mIU/mL for LH, 0.1 mIU/mL for FSH, and 18.4 pmol/L for E2. Serum TSH and fT4 levels were analyzed with Beckman Coulter DxI 800 Access® immunoassay system (Beckman Coulter, USA).
Yigit O., Sert T.K., Ekinci D., Kirankaya A, & Kilinc S. (2023). The effect of subclinical hypothyroidism on ovarian volume in prepubertal girls. Northern Clinics of Istanbul, 10(1), 48-52.
Publication 2023
A-A-1 antibiotic Centrifugation Chemiluminescent Assays Diagnosis Estradiol Human Follicle Stimulating Hormone Hypersensitivity Immunoassay Light Luteinizing hormone Ovarian Cysts Ovary Patients Pelvic Examination Pelvis Serum Ultrasonography Veins
5
Ovulation Stimulation Protocol for IVF
Ovulation stimulation was managed by OHSU REI physicians and followed established standards of care using a combination of self-administered injectable gonadotropins following 3–4 weeks ovarian suppression with combined oral contraceptives. Study participants self-administered medications for 8–12 days; the starting Follicle Stimulating Hormone (FSH) dose was 75–125 IU/day human Menopausal Gonadotropins (hMG) was adjusted per individual response using an established step-down regimen until the day of human chorionic gonadotropin (hCG) injection. Gnrh antagonist was administered when the lead follicle was 14 mm in size. Subjects underwent ultrasound monitoring, and blood draws for estradiol levels. hCG and/or Lupron was administered when two or more follicles measured >18 mm in diameter. Subjects underwent oocyte retrieval via transvaginal follicular aspiration 35 h after hCG.
Liang D., Mikhalchenko A., Ma H., Marti Gutierrez N., Chen T., Lee Y., Park S.W., Tippner-Hedges R., Koski A., Darby H., Li Y., Van Dyken C., Zhao H., Wu K., Zhang J., Hou Z., So S., Han J., Park J., Kim C.J., Zong K., Gong J., Yuan Y., Gu Y., Shen Y., Olson S.B., Yang H., Battaglia D., O’Leary T., Krieg S.A., Lee D.M., Wu D.H., Duell P.B., Kaul S., Kim J.S., Heitner S.B., Kang E., Chen Z.J., Amato P, & Mitalipov S. (2023). Limitations of gene editing assessments in human preimplantation embryos. Nature Communications, 14, 1219.
Full text: Click here
Publication 2023
Combined Oral Contraceptives Estradiol Gonadorelin Gonadotropins Hair Follicle Human Chorionic Gonadotropin Human Follicle Stimulating Hormone Lupron Menotropins Oocyte Retrieval Ovarian Follicle Ovary Ovulation Pharmaceutical Preparations Phlebotomy Physicians Treatment Protocols Ultrasonography

Top products related to «Human Follicle Stimulating Hormone»

1
Gonal f by Merck Group
Sourced in Switzerland, Germany, Italy, France, United States, Spain, Netherlands, United Kingdom, Australia, Japan, Denmark, Brazil, China
Gonal-F is a recombinant human follicle-stimulating hormone (r-hFSH) produced by recombinant DNA technology. It is used as a fertility medication to stimulate follicular development and maturation in the ovary as part of an assisted reproductive technology (ART) program.
2
Tcm 199 by Thermo Fisher Scientific
Sourced in United States, Spain, Canada, Denmark, Belgium, Japan
TCM-199 is a cell culture medium developed for the in vitro cultivation of various cell types, including mammalian cells. It provides the necessary nutrients and growth factors to support cell growth and maintenance. The formulation is designed to maintain the physiological pH and osmolality required for optimal cell performance.
3
Cetrotide by Merck Group
Sourced in Germany, Switzerland, United Kingdom, Spain, France, Netherlands, United States, Japan
Cetrotide is a laboratory product manufactured by Merck Group. It is a synthetic peptide that acts as a gonadotropin-releasing hormone (GnRH) antagonist. The core function of Cetrotide is to inhibit the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland.
4
Ovidrel by Merck Group
Sourced in Switzerland, Germany, Italy, United States, Brazil, Australia
Ovidrel is a laboratory product manufactured by Merck Group. It is a recombinant human chorionic gonadotropin (hCG) medication used for in vitro fertilization (IVF) procedures. Ovidrel is designed to trigger the final stage of egg maturation prior to ovulation.
5
Ovitrelle by Merck Group
Sourced in Germany, Switzerland, France, Italy, United Kingdom, Netherlands
Ovitrelle is a laboratory product manufactured by Merck Group. It is a gonadotropin-releasing hormone agonist used in in-vitro fertilization procedures.
6
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
7
Menopur by Ferring
Sourced in Switzerland, Germany, United States, Denmark, Canada, Belgium, Spain, China, France, Sweden, United Kingdom
Menopur is a medication used in assisted reproductive technology (ART) procedures. It contains a mixture of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which are hormones that play a crucial role in the development and maturation of ovarian follicles.
8
Pregnyl by Organon
Sourced in Netherlands, Australia, Germany, United States
Pregnyl is a laboratory product used for the measurement of human chorionic gonadotropin (hCG) levels. It is a highly purified form of hCG, a naturally occurring hormone produced during pregnancy. Pregnyl can be used as a reference standard or calibrator in assays designed to detect and quantify hCG in biological samples.

More about "Human Follicle Stimulating Hormone"

Human Follicle Stimulating Hormone (hFSH) is a vital glycoprotein hormone produced by the anterior pituitary gland.
It plays a crucial role in regulating reproductive function in both males and females.
In females, hFSH stimulates the growth and development of follicles in the ovary, as well as the production of estrogen.
In males, hFSH stimulates the Sertoli cells in the testes, which are responsible for supporting and nourishing the developing sperm cells.
Optimizing hFSH research is essential for understanding and treating various reproductive disorders, such as infertility, polycystic ovary syndrome (PCOS), and hypogonadism.
Gonal-F, TCM-199, Cetrotide, Ovidrel, Ovitrelle, and Menopur are some of the key pharmaceutical products and cell culture media used in hFSH research and reproductive medicine.
FBS (Fetal Bovine Serum) is a commonly used supplement in cell culture media, while Pregnyl is a medication containing human chorionic gonadotropin (hCG), which can be used in conjunction with hFSH to stimulate ovulation and support early pregnancy.
By utilizing the powerful tools and insights provided by PubCompare.ai, researchers can optimize their hFSH studies, enhance reproducibility, and identify the most effective protocols and products.
PubCompare.ai's AI-driven comparisons and comprehensive literature analysis can help researchers stay at the forefront of this critical field of study, ultimately leading to improved understanding and treatment of reproductive disorders.